Hematologic side effects of psychotropics

Psychosomatics

Volumn 40, Issue 5, 1999, Pages 414-421

  Oyesanmi, Olu ^b   Kunkel, Elisabeth J S ^a   Monti, Daniel A ^b   Field, Howard L ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIAZEPAM; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE MALEATE; HALOPERIDOL; IMIPRAMINE; LITHIUM; LOXAPINE SUCCINATE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; OXAZEPAM; PSYCHOTROPIC AGENT; RISPERIDONE; TRANYLCYPROMINE; TRAZODONE; VENLAFAXINE;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; BLOOD TOXICITY; EOSINOPHILIA; HUMAN; LIAISON PSYCHIATRY; NEUTROPENIA; PANCYTOPENIA; PSYCHIATRIST; THROMBOCYTOPENIA;

EID: 0032818658     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0033-3182(99)71206-5     Document Type: Article

References (52)

1. Galbaud du Fort G: Hematologic toxicity of antidepressive agents. Encephale 1998; 14:307-318
2. Baldessarini RJ: Drugs and the treatment of psychiatric disorders, in The Pharmacological Basis of Therapeutics, 6th Edition, edited by Gilman AG, Goldman LS, Gilman A. New York, Macmillan, 1980, pp. 391-447
3. Joffe RT, Kellner CH, Post RM, et al: Lithium increases platelet count. N Engl J Med 1984; 311:674-675
4. Moses RA: Drug-induced immune thrombocytopenia. Am J Hematol 1980; 9:439-446
5. Balon R, Berchou R: Hematologic side effects of psychotropic drugs. Psychosomatics 1986; 27:119-120
6. Kronfold Z, Turner R, Nasrallah H, et al: Leukocyte regulation in depression and schizophrenia. Psychiatr Res 1984; 13:13-18
7. Goosland I, Seed M, Simpson R, et al: Comparison of hematologic indices between women of four ethnic groups and the effect of oral contraception. J Clin Pathol 1983; 36:184-191
8. DuComb L, Baldesarini RJ: Timing and risk of bone marrow depression by psychotropic drugs. Am J Psychiatry 1977; 134:1294-1295
9. Kealing RP: Non-neoplastic disorders of granulocytes and monocytes, in Fundamentals of Clinical Hematology, 5th Edition, edited by Leavell BS, Thorup OA. Philadelphia, PA, WB Saunders, 1987, pp. 425-459
10. Levin GM, DeVane CL: A review of cyclic antidepressant-induced blood dyscrasias. Ann Pharmacother 1992; 26:378-383.
11. Pisciotta AV: Drug-induced leukopenia and aplastic anemia. Clin Pharmacol Ther 1971; 12:13-43
12. Castro-Malaspina H, O'Reilly RJ: Aplastic anemia and myelodysplasia, in Harrison's Principles of Internal Medicine, Vol 1, 14th Edition, edited by Fauci AJ, Braunwald E, Isselbacher KJ, et al. New York, McGraw-Hill, 1998, p. 674
13. Graubert TA: Disorders of hemostasis, in The Washington Manual of Therapeutics, 29th Edition, edited by Carey CF, Lee HH, Woeltje KF. Philadelphia, PA, Lippincott-Raven, 1998, pp. 342-357
14. Bithell TC: Disorders of platelets, in Fundamentals of Clinical Hematology, 5th Edition, edited by Leavell BS, Thorup OA Jr. Philadelphia, PA, WB Saunders, 1987, pp. 792-823
15. Buckley PF, Meltzer HY: Treatment of schizophrenia, in The Textbook of Psychopharmacology, 1st Edition, edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, p. 627
16. Gerson SL, Meltzer HY: Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992; 7:17-25
17. Honigfeld G, Arellano F, Sethi J, et al: Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59(suppl 3):3-7
18. Chatterton R: Eosinophilia after commencement of clozapine treatment. Aust N Z J Psychiatry 1997; 31:874-876
19. Lieberman JA, Alvir JMJ: A report of clozapine-induced agranulocytosis in the United States: incidence and risk factors. Drug Saf 1992; 7(suppl 1):1-2
20. Alebertini RS, Penders TM: Agranulocytosis associated with tricyclics. J Clin Psychiatry 1978; 39:483-485
21. Gravenor DS, Leclerc JR, Blake G: Tricyclic antidepressant agranulocytosis. Can J Psychiatry 1986; 31:661
22. MICROMEDEX™ (Healthcare Series Integrated Index™ Search. Denver, CO, MICROMEDEX, 1998
23. Goldberg RJ: Selective serotonin reuptake inhibitors: infrequent medical adverse effects. Arch Fam Med 1998; 7:78-84
24. Hourani S, Cusack N: Pharmacologic receptors on blood platelets. Pharmacol Rev 1991; 43:243-298
25. Declerck F: The role of serotonin in thrombogenesis. Clinical Physiology and Biochemistry 1991; 8(suppl 3):40-49
26. Skop B, Brown T: Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37:12-16
27. Pai VB, Kelly MW: Bruising associated with the use of fluoxetine. Ann Pharmacother 1996; 30:786-788
28. Celeda P, Dolera M, Alvarez E: Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J Affect Disord 1992; 25:243-249
29. Goldstein J, deMorais S: Biochemistry and molecular biology of human CYP2C subfamily. Pharmacogenetics 1994; 4:285-299
30. Pierce DW, Glassman AH: Treatment of depression in patients with heart disease. J Pract Psychiatry Behav Health 1998; 4:140-149
31. Beliles K, Stoudemire A: Psychopharmacological treatment of depression in the medically ill. Psychosomatics 1998; 39(suppl):S2-S19
32. Stoudemire A, Fogel BS: Psychopharmacology in medical patients, in Medical-Psychiatric Practice, Vol 3, edited by Stoudemire A, Fogel BS. Washington, DC, American Psychiatric Press, 1995, pp. 79-149
33. Cimo PL, Pisciotta AV, Desai RG, et al: Detection of drug-independent antibodies by the 51Cr platelet lysis test: documentation of immune thrombocytopenia induced by diphenylhydantoin, diazepam, and sulfisoxazole. Am J Hematol 1997; 2:65-72
34. Stein RS, Howard CA, Brennan M, et al: Lithium carbonate and granulocyte production: dose optimization. Cancer 1981; 48:269-270
35. Medina JC, Fareed J, Diamond S: Lithium carbonate therapy for cluster headache: changes in number of platelets, serotonin, and histamine levels. Arch Neurol 1980; 37:559-563
36. Hayes PC, Hargreaves LN: Lithium inhibition of ristocetin-induced fibrinogen precipitation. Thromb Res 1978; 12:567-568
37. Fischl MA, Richman DD, Grieco MH, et al: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185-191
38. Rall TW, Schleifer LS: Drugs effective in the therapy of the epilepsies, in The Pharmacological Basis of Therapeutics, 6th Edition, edited by Gilman AG, Goldman LS, Gilman A. New York, Macmillan, 1980, pp. 448-474
39. Brewerton TD: Lithium counteracts carbamazepine-induced leukopenia while increasing its therapeutic effect. Biol Psychiatry 1986; 21:677-685
40. Vieweg WVR, Yank GR, Row WT, et al: Increase in white blood cell count and serum sodium level following the addition of lithium to carbamazepine treatment among three chronically psychotic male patients with disturbed affective states. Psychiatr Q 1986; 58:213-317
41. Ozkara C, Dreifuss FE, Apperson-Hansen C: Changes in red blood cells with valproate therapy. Acta Neurol Scand 1993; 88:210-212
42. Dulcan MK, Bregman JD, Weller BE, et al: Treatment of childhood and adolescent disorders, in The Textbook of Psychopharmacology, 1st Edition, edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp. 680-697
43. Young LT, Robb JC, Patelis-Siotis I, et al: Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997; 42:851-853
44. Fatemi SH, Rapport DJ, Calabrese JR, et al: Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997; 58:522-527
45. Betts T, Goodwin G, Withers RM, et al: Human safety of lamotrigine. Epilepsia 1991; 32(suppl 2):S17-S21
46. Cocito L, Maffini M, Loeb C: Long-term observation on the clinical use of lamotrigine as an add-on drug in patients with epilepsy. Epilepsy Res 1994;19:123-127
47. x. St Louis, MO, Mosby-Year Book, 1998
48. Ramsay RE: Clinical efficacy and safety of gabapentin. Neurology 1994; 44(suppl 5):S23-S30
49. Fauci AJ, Braunwald E, Isselbacher KJ, et al: Hematologic evaluations, in Harrison's Principles of Internal Medicine, Vol 1, 14th Edition, edited by Fauci AJ, Braunwald E, Isselbacher KJ, et al. New York, McGraw-Hill, 1998, Appendix A-5
50. Pocket Prescribing: The Guide to Psychotropic Agents. Secaucus, NJ, Pocket Prescribing, 1997
51. Medical Economics Company: Physicians' Desk Reference, 51st Edition. Montvale, NJ, Medical Economics Company, 1997
52. Stahl SM: Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998; 59(suppl 4):5-14